What insurance typically covers FDA-approved peptides for approved indications: Semaglutide (Ozempic) for type 2 diabetes: Often covered Semaglutide (Wegovy) for obesity: Sometimes covered with restrictions Tirzepatide (Mounjaro) for type 2 diabetes: Often covered Tirzepatide (Zepbound) for obesity: Limited coverage What coverage looks like: Prior authorization typically required Documentation of failed dietary interventions BMI thresholds for weight loss indications Co-pays still substantial ($100-500 monthly) What insurance doesn't cover The vast majority of peptide therapy falls outside insurance coverage: Compounded peptides (BPC-157, TB-500, most growth hormone peptides) Anti-aging applications even for FDA-approved drugs Performance enhancement uses Off-label applications These costs are entirely out-of-pocket for most patients
Histology Lungs were collected and stored in 10% neutral buffered formalin
In hippocampal neuron cultures, Dihexa was reported to induce spinogenesis and synaptogenesis at picomolar concentrations the basis for the widely-cited seven orders of magnitude more potent than BDNF potency figure
Wang L, Xu R, Kaelber DC, et al
Texts may be sent using SMS, MMS, or RCS technology
Nevertheless, no clinical trials are available, extract standardization is lacking, and positive pharmacological comparators (e.g., PDE5 inhibitors) have not been used in animal models
